Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.

Fabian Trillsch,Sven Mahner,Beyhan Ataseven,Rebecca Asher,Coraline Dubot,Andrew R Clamp,Richard T. Penson,Amit M. Oza,Amnon Amit,Tomasz Huzarski,Antonio Casado,Giovanni Scambia,Michael Friedlander,Nicoletta Colombo,Keiichi Fujiwara,Gabe S. Sonke,Hannelore Denys,Elizabeth S. Lowe,Eric Pujade Lauraine

Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.

2020

Fabian Trillsch
Sven Mahner
Beyhan Ataseven
Rebecca Asher
Coraline Dubot
Andrew R Clamp
Richard T. Penson
Amit M. Oza
Amnon Amit
Tomasz Huzarski
Antonio Casado
Giovanni Scambia
Michael Friedlander
Nicoletta Colombo
Keiichi Fujiwara
Gabe S. Sonke
Hannelore Denys
Elizabeth S. Lowe
Eric Pujade Lauraine

6068Background: Adding olaparib as maintenance treatment to BRCA-1/2 mutated patients (pts) with recurrent platinum-sensitive ovarian cancer (PSOC) has significantly improved progression-free survi...

Keywords:

Oncology
Olaparib
Internal medicine
Ovarian cancer
Pathology
Medicine
platinum sensitive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations